Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
Javed Anees/LinkedIn
Jul 8, 2026, 19:26

Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy

Javed Anees, Medical Consultant at Government of Kerala, shared a post on LinkedIn:

“Erythropoiesis-Stimulating Agents (ESAs) have transformed the management of anemia in chronic kidney disease and selected oncology patients by reducing transfusion requirements and improving quality of life. However, appropriate patient selection, correction of reversible causes, and careful monitoring remain essential to maximize benefit while minimizing cardiovascular and thromboembolic risks.

This evidence-based infographic summarizes:

  • Indications for ESA therapy
  • When to initiate treatment in CKD and dialysis
  • Pre-treatment evaluation and iron optimization
  • Target hemoglobin and dose adjustment
  • Contraindications and adverse effects
  • Causes of ESA hyporesponsiveness
  • HIF-prolyl hydroxylase inhibitors and other alternatives
  • Practical clinical pearls aligned with current guideline recommendations

A key reminder:

ESA therapy should be individualized – not driven by hemoglobin alone. Correct iron deficiency and other reversible causes first, use the lowest effective ESA dose to reduce transfusion needs, and avoid targeting normal hemoglobin levels. In most CKD patients, a hemoglobin around 10–11.5 g/dL is the preferred therapeutic range.

I hope this infographic serves as a concise, practical reference for residents, physicians, nephrologists, internists, and trainees involved in anemia management.”

Javed Anees

Other posts featuring Javed Anees on Hemostasis Today.

anemia bleeding disorders Blood cardiovascular risk Chronic Kidney Disease CKD Erythropoiesis-Stimulating Agents ESAs Health Hematology Hemoglobin Hemostasis News Hemostasis Today HIF-prolyl hydroxylase Iron Iron deficiency anaemia Javed Anees Medicine Oncology RBC thromboembolic risk
NewsFeed